Tocilizumab in COVID-19 interstitial pneumonia.
J Intern Med
; 289(5): 738-746, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1054555
ABSTRACT
BACKGROUND:
Published reports on tocilizumab in COVID-19 pneumonitis show conflicting results due to weak designs or heterogeneity in critical methodological issues.METHODS:
This open-label trial, structured according to Simon's optimal design, aims to identify factors predicting which patients could benefit from anti-IL6 strategies and to enhance the design of unequivocal and reliable future randomized trials. A total of 46 patients with COVID-19 pneumonia needing of oxygen therapy to maintain SO2 > 93% and with recent worsening of lung function received a single infusion of tocilizumab. Clinical and biological markers were measured to test their predictive values. Primary end point was early and sustained clinical response.RESULTS:
Twenty-one patients fulfilled pre-defined response criteria. Lower levels of IL-6 at 24 h after tocilizumab infusion (P = 0.049) and higher baseline values of PaO2/FiO2 (P = 0.008) predicted a favourable response.CONCLUSIONS:
Objective clinical response rate overcame the pre-defined threshold of 30%. Efficacy of tocilizumab to improve respiratory function in patients selected according to our inclusion criteria warrants investigations in randomized trials.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Interleucina-6
/
Monitoreo de Drogas
/
Biomarcadores Farmacológicos
/
Anticuerpos Monoclonales Humanizados
/
COVID-19
Tipo de estudio:
Estudios diagnósticos
/
Estudio experimental
/
Estudio observacional
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
Límite:
Anciano
/
Femenino
/
Humanos
/
Masculino
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
J Intern Med
Asunto de la revista:
Medicina Interna
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Joim.13231
Similares
MEDLINE
...
LILACS
LIS